A Study of the Efficacy and Safety of Rizatriptan 10 mg RPD in the Treatment of Acute Migraine in Patients With Non Satisfactory Response to Previous Pharmacologic Treatment.

Trial Profile

A Study of the Efficacy and Safety of Rizatriptan 10 mg RPD in the Treatment of Acute Migraine in Patients With Non Satisfactory Response to Previous Pharmacologic Treatment.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2013

At a glance

  • Drugs Rizatriptan (Primary) ; Analgesics; Tryptamines
  • Indications Migraine with aura; Migraine without aura
  • Focus Therapeutic Use
  • Acronyms Rinotama
  • Most Recent Events

    • 25 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Jun 2011 Interim results (n=95) presented at the 15th Congress of the International Headache Society.
    • 26 Jun 2011 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top